Web Desc
Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit
Organizer(s): Padmanee Sharma, Aviv Regev, Crystal L. Mackall and Kristen Hege
Date: March 10 - 14, 2019
Location: Whistler Conference Centre, Whistler, BC, Canada
Sponsored by Autolus Therapeutics, Bayer AG, BioLegend, Inc., Bristol-Myers Squibb Company, Cell Research, ImmunoGen, Inc., Incyte Corporation, MedImmune, Merck & Co., Inc., Roche, Surface Oncology, TESARO, Inc., Takeda Pharmaceutical Company Limited and Tessa Therapeutics Ltd.
For important information on the coronavirus, please click here
Summary of Meeting:
Cancer immunotherapy is an established field that has led to remarkable clinical benefit for a subset of patients. However, a deeper understanding of the mechanisms of response and resistance to current immunotherapy strategies is needed to help develop new treatments that will increase the number of patients who will benefit. This Keystone Symposia conference is focused on immunotherapy as a treatment for cancer, including potential combination therapies and development of new technologies to elucidate novel targets and/or biomarkers that will be used to design new treatments and enable appropriate patient selection to improve clinical outcomes for cancer patients. The conference will bring together leading and emerging scientists to advance the development of new immune-based treatments for cancer. Discussions will also consider the future directions of the field, including the identification of the most pressing unanswered questions, the areas needing more focus, and those that would benefit from new approaches and methodologies developed and used in other related fields.
Scholarship Deadline: November 20 2018
Discounted Abstract Deadline: November 20 2018
Abstract Deadline: December 5 2018
Discounted Registration Deadline: January 15 2019
Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.


Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Autolus TherapeuticsBayer AGBioLegend, Inc.Bristol-Myers Squibb CompanyCell ResearchImmunoGen, Inc.Incyte CorporationMedImmuneMerck & Co., Inc.RocheSurface OncologyTakeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company LimitedTESARO, Inc.Tessa Therapeutics Ltd.
We gratefully acknowledge additional support from these exhibitors at this conference:
PeproTech, Inc.10x Genomics
We gratefully acknowledge additional support for this conference from:
American Association for Cancer Research (AACR)American Society of Gene & Cell Therapy (ASGCT)eLifeInSphero Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Amgen Inc.

Arcus Biosciences, Inc.

Celgene Corporation

Forty Seven, Inc.

Jounce Therapeutics, Inc.

Kyn Therapeutics

Nektar Therapeutics
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA236284-01
Funding for this conference was made possible (in part) by 1R13CA236284-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, March 10 | 4:00PM - 8:00PM
Arrival and Registration
Room: Grand Foyer


Sunday, March 10 | 6:00PM - 8:00PM
Welcome Mixer
Room: Grand Foyer
No registration fees are used to fund alcohol served at this function.

Monday, March 11 | 7:00AM - 8:00AM
Breakfast
Room: Grand Foyer


Monday, March 11 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Sea to Sky B/C

Speaker 1 of 2
* Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA

Monday, March 11 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Sea to Sky B/C

Speaker 2 of 2
Catherine J. Wu, Dana-Farber Cancer Institute, USA
Identifying and Targeting Tumor Neoantigens

Monday, March 11 | 9:00AM - 11:30AM
Response and Resistance Mechanisms to Cancer Immunotherapy
Room: Sea to Sky B/C

Speaker 1 of 6
* Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy

Monday, March 11 | 9:00AM - 11:30AM
Response and Resistance Mechanisms to Cancer Immunotherapy
Room: Sea to Sky B/C


Coffee Break

Monday, March 11 | 9:00AM - 11:30AM
Response and Resistance Mechanisms to Cancer Immunotherapy
Room: Sea to Sky B/C

Speaker 3 of 6
Philip D. Greenberg, University of Washington, USA
Resistance Mechanisms to Engineered T Cell Therapies

Monday, March 11 | 9:00AM - 11:30AM
Response and Resistance Mechanisms to Cancer Immunotherapy
Room: Sea to Sky B/C

Speaker 4 of 6
* Robert D. Schreiber, Washington University School of Medicine, USA
The Molecular Cell Biology of Immune Control and Escape of Cancer

Monday, March 11 | 9:00AM - 11:30AM
Response and Resistance Mechanisms to Cancer Immunotherapy
Room: Sea to Sky B/C

Speaker 5 of 6
Yuliya Pylayeva-Gupta, University of North Carolina at Chapel Hill, USA
Short Talk: IL-35+ B Cells Establish Immunosuppressive Network in Pancreatic Ductal Adenocarcinoma

Monday, March 11 | 9:00AM - 11:30AM
Response and Resistance Mechanisms to Cancer Immunotherapy
Room: Sea to Sky B/C

Speaker 6 of 6
Robert T. Manguso, Massachusetts General Hospital, USA
Short Talk: Loss of ADAR1 in Tumors Overcomes Resistance to Immune Checkpoint Blockade

Monday, March 11 | 11:30AM - 5:00PM
On Own for Lunch


Monday, March 11 | 11:30AM - 1:00PM
Poster Setup
Room: Sea to Sky A


Monday, March 11 | 1:00PM - 10:00PM
Poster Viewing
Room: Sea to Sky A


Monday, March 11 | 2:30PM - 4:30PM
Workshop 1: Engaging New Mechanisms to Improve Cancer Immuno
therapy
Room: Sea to Sky B/C

Speaker 1 of 7
Donald E. Staunton, Arbele Corporation, USA
Bispecific CDH17/CD3 Antibodies with High Tumor Specificity, Cytotoxicity and Safety in Non-Human Primates

Monday, March 11 | 2:30PM - 4:30PM
Workshop 1: Engaging New Mechanisms to Improve Cancer Immuno
therapy
Room: Sea to Sky B/C

Speaker 2 of 7
Krzysztof Masternak, NovImmune SA, Switzerland
CD47-Blocking Bispecific Antibodies Increase in vivo Phagocytosis of Tumor Cells and Modify the Tumor Microenvironment

Monday, March 11 | 2:30PM - 4:30PM
Workshop 1: Engaging New Mechanisms to Improve Cancer Immuno
therapy
Room: Sea to Sky B/C

Speaker 3 of 7
Limei Shen, University of North Carolina, USA
Nano-trapping B Cell Chemoattractant CXCL13 Reduces Bregs in Tumor Microenvironment and Inhibits Desmoplastic Tumors in Murine Orthotopic Models

Monday, March 11 | 2:30PM - 4:30PM
Workshop 1: Engaging New Mechanisms to Improve Cancer Immuno
therapy
Room: Sea to Sky B/C

Speaker 4 of 7
Adrienne H. Long, Dana-Farber Cancer Institute, USA
Inhibition of Signal Peptide Peptidase Triggers Novel Antigen Presentation on Non-Classical MHC and Sensitizes Tumors to Checkpoint Blockade

Monday, March 11 | 2:30PM - 4:30PM
Workshop 1: Engaging New Mechanisms to Improve Cancer Immuno
therapy
Room: Sea to Sky B/C

Speaker 5 of 7
* Shruthy Suresh, University of Texas Southwestern Medical Center, USA
The Integrated Stress Response Pathway Controls PD-L1 Translation in Lung Cancer

Monday, March 11 | 2:30PM - 4:30PM
Workshop 1: Engaging New Mechanisms to Improve Cancer Immuno
therapy
Room: Sea to Sky B/C

Speaker 6 of 7
Andrew G. Thomason, Redx Pharma, UK
Wnt Pathway Suppression with Porcupine Inhibitor RXC004 Enhances the Immune Response against Tumours

Monday, March 11 | 2:30PM - 4:30PM
Workshop 1: Engaging New Mechanisms to Improve Cancer Immuno
therapy
Room: Sea to Sky B/C

Speaker 7 of 7
* Patrick A. Ott, Dana-Farber Cancer Institute, USA
Complex Inter-Relationship of Body Mass Index, Gender and Serum Creatinine on Survival: Exploring the Obesity Paradox in Melanoma Patients Treated with Immune Checkpoint Inhibition

Monday, March 11 | 4:30PM - 5:00PM
Coffee Available
Room: Grand Foyer


Monday, March 11 | 5:00PM - 7:00PM
Technological Advances for Dissecting Immune Responses
Room: Sea to Sky B/C

Speaker 1 of 5
* Elaine R. Mardis, Nationwide Children's Hospital, USA
Genomic Exploration of the Pediatric CNS Tumor Microenvironment

Monday, March 11 | 5:00PM - 7:00PM
Technological Advances for Dissecting Immune Responses
Room: Sea to Sky B/C

Speaker 2 of 5
* Michael Angelo, Stanford University, USA
Mapping the Immune Landscape in Solid Tumors using MIBI

Monday, March 11 | 5:00PM - 7:00PM
Technological Advances for Dissecting Immune Responses
Room: Sea to Sky B/C

Speaker 3 of 5
James P. Allison, University of Texas MD Anderson Cancer Center, USA
Immune Checkpoint Therapy: Lessons Learned and Next Steps

Monday, March 11 | 5:00PM - 7:00PM
Technological Advances for Dissecting Immune Responses
Room: Sea to Sky B/C

Speaker 4 of 5
Jonathan Fisher, University College London, UK
Short Talk: Mass Cytometric Analysis of CAR Signaling – Single Cell Engine Diagnostics Reveals Problems and Solutions

Monday, March 11 | 5:00PM - 7:00PM
Technological Advances for Dissecting Immune Responses
Room: Sea to Sky B/C

Speaker 5 of 5
Martin LaFleur, Harvard Medical School, USA
Short Talk: CHIME: A Chimeric CRISPR-Cas9 Delivery System for Pooled in vivo Screening of Genes in the Immune System

Monday, March 11 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Sea to Sky A
No registration fees are used to fund alcohol served at this function.

Monday, March 11 | 7:30PM - 10:00PM
Poster Session 1
Room: Sea to Sky A


Tuesday, March 12 | 7:00AM - 8:00AM
Breakfast
Room: Grand Foyer


Tuesday, March 12 | 8:00AM - 11:00AM
Improving Anti-Tumor Immune Responses
Room: Sea to Sky B/C

Speaker 1 of 6
* Aviv Regev, Massachusetts Institute of Technology, USA
Comprehending Anti-Tumor Immune Responses through Single-Cell Studies

Tuesday, March 12 | 8:00AM - 11:00AM
Improving Anti-Tumor Immune Responses
Room: Sea to Sky B/C

Speaker 2 of 6
Elizabeth G. Trehu, Jounce Therapeutics, USA
Lessons Learned from Clinical Trials Targeting ICOS

Tuesday, March 12 | 8:00AM - 11:00AM
Improving Anti-Tumor Immune Responses
Room: Sea to Sky B/C


Coffee Break

Tuesday, March 12 | 8:00AM - 11:00AM
Improving Anti-Tumor Immune Responses
Room: Sea to Sky B/C

Speaker 4 of 6
Thomas Gajewski, University of Chicago, USA
Identifying Mechanisms to Facilitate a T Cell-Inflamed Tumor Microenvironment

Tuesday, March 12 | 8:00AM - 11:00AM
Improving Anti-Tumor Immune Responses
Room: Sea to Sky B/C

Speaker 5 of 6
* Niroshana Anandasabapathy, Weill Cornell Medicine, USA
Targeting T Cell:DC Cross Talk in the Periphery to Expand Anti-Tumor Immunity

Tuesday, March 12 | 8:00AM - 11:00AM
Improving Anti-Tumor Immune Responses
Room: Sea to Sky B/C

Speaker 6 of 6
Shannon K. Oda, Fred Hutchinson Cancer Research Center, USA
Short Talk: A Fas-4-1BB Immunomodulatory Fusion Protein Enhances Function and Metabolism of Engineered T cells and Improves Immunotherapy of Liquid and Solid Tumors

Tuesday, March 12 | 11:00AM - 5:00PM
On Own for Lunch


Tuesday, March 12 | 11:00AM - 1:00PM
Poster Setup
Room: Sea to Sky A


Tuesday, March 12 | 1:00PM - 10:00PM
Poster Viewing
Room: Sea to Sky A


Tuesday, March 12 | 2:30PM - 4:30PM
Workshop 2: Engineered T Cells
Room: Sea to Sky B/C

Speaker 1 of 8
Mauro Castellarin, University of Pennsylvania, USA
A Universal Chimeric Antigen Receptor System for Switching Target Recognition by CAR T Cells

Tuesday, March 12 | 2:30PM - 4:30PM
Workshop 2: Engineered T Cells
Room: Sea to Sky B/C

Speaker 2 of 8
Philip S. Low, Purdue University, USA
Evaluation of a Universal CAR T Cell Technology in Murine Tumor Models

Tuesday, March 12 | 2:30PM - 4:30PM
Workshop 2: Engineered T Cells
Room: Sea to Sky B/C

Speaker 3 of 8
Louai Labanieh, Stanford University, USA
Controlling CAR-T Function with an FDA-Approved Small Molecule

Tuesday, March 12 | 2:30PM - 4:30PM
Workshop 2: Engineered T Cells
Room: Sea to Sky B/C

Speaker 4 of 8
Henri Bayle, Bellicum Pharmaceuticals, USA
Control of CAR-Natural Killer Cell Expansion and Anti-Tumor Activity with Inducible MyD88/CD40 and Small Molecules

Tuesday, March 12 | 2:30PM - 4:30PM
Workshop 2: Engineered T Cells
Room: Sea to Sky B/C

Speaker 5 of 8
Tori Yamamoto, NCI, University of Pennsylvania, USA
T Cells Engineered to Overcome Death Signaling within the Tumor Microenvironment Enhance Adoptive Cancer Immunotherapy

Tuesday, March 12 | 2:30PM - 4:30PM
Workshop 2: Engineered T Cells
Room: Sea to Sky B/C

Speaker 6 of 8
Robert J. Hofmeister, TCR2 Therapeutics, USA
Preclinical Evaluation of TC-210, a Mesothelin-Specific T Cell Receptor (TCR) Fusion Construct (TRuC™) T Cells for the Treatment of Solid Tumors

Tuesday, March 12 | 2:30PM - 4:30PM
Workshop 2: Engineered T Cells
Room: Sea to Sky B/C

Speaker 7 of 8
* Beatrice Greco, Vita-Salute San Raffaele University, Italy
Combining De-Glycosylating Agents with CAR-T Cells for Targeting Solid Tumors and Reducing Toxicity

Tuesday, March 12 | 2:30PM - 4:30PM
Workshop 2: Engineered T Cells
Room: Sea to Sky B/C

Speaker 8 of 8
* Melody Smith, Memorial Sloan Kettering Cancer Center, USA
Intestinal Microbiome Analyses Identify Biomarkers for Patient Response to CAR T Cell Therapy

Tuesday, March 12 | 4:30PM - 5:00PM
Coffee Available
Room: Grand Foyer


Tuesday, March 12 | 5:00PM - 7:00PM
Engineering T Cells
Room: Sea to Sky B/C

Speaker 1 of 5
* Crystal L. Mackall, Stanford University, USA
Engineering Exhaustion Resistant T Cells to Enhance the Efficacy of CAR-Based Therapies

Tuesday, March 12 | 5:00PM - 7:00PM
Engineering T Cells
Room: Sea to Sky B/C

Speaker 2 of 5
* Kristen Hege, Celgene, USA
Clinical Development of BCMA CAR T Cells in Myeloma

Tuesday, March 12 | 5:00PM - 7:00PM
Engineering T Cells
Room: Sea to Sky B/C

Speaker 3 of 5
Carl H. June, University of Pennsylvania, USA
CAR T Cell Therapies: Lessons Learned and Next Steps

Tuesday, March 12 | 5:00PM - 7:00PM
Engineering T Cells
Room: Sea to Sky B/C

Speaker 4 of 5
Megan M. Dacek, Memorial Sloan Kettering Cancer Center, USA
Short Talk: Potentiating Innate and Adaptive Immunity with Engineered CAR T Cells

Tuesday, March 12 | 5:00PM - 7:00PM
Engineering T Cells
Room: Sea to Sky B/C

Speaker 5 of 5
Evan William Weber, Stanford University, USA
Short Talk: Transient Rest Reverses CAR T Cell Exhaustion and Augments Efficacy

Tuesday, March 12 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Sea to Sky A
No registration fees are used to fund alcohol served at this function.

Tuesday, March 12 | 7:30PM - 10:00PM
Poster Session 2
Room: Sea to Sky A


Wednesday, March 13 | 7:00AM - 8:00AM
Breakfast
Room: Grand Foyer


Wednesday, March 13 | 8:00AM - 11:15AM
Immune Checkpoints: Basic Mechanisms and Novel Targets
Room: Sea to Sky B/C

Speaker 1 of 8
Chris H. Takimoto, Forty Seven, Inc., USA
Enhancing Antitumor Immunity by Inhibiting CD47 Signaling: An Overview of CD47 Targeting Agents in Clinical Development

Wednesday, March 13 | 8:00AM - 11:15AM
Immune Checkpoints: Basic Mechanisms and Novel Targets
Room: Sea to Sky B/C

Speaker 2 of 8
* Sangeeta Goswami, MD Anderson Cancer Center, USA
Modulation of Immune Checkpoint Therapy Responses by Immune Cell Inherent Epigenetic Machinery

Wednesday, March 13 | 8:00AM - 11:15AM
Immune Checkpoints: Basic Mechanisms and Novel Targets
Room: Sea to Sky B/C


Coffee Break

Wednesday, March 13 | 8:00AM - 11:15AM
Immune Checkpoints: Basic Mechanisms and Novel Targets
Room: Sea to Sky B/C

Speaker 4 of 8
Willem W. Overwijk, Nektar Therapeutics, USA
Intratumoral Expansion of CD8+ T cells and Depletion of Tregs after Treatment with NKTR-214, a First-In-Class, CD122-Preferential IL-2 Pathway Agonist

Wednesday, March 13 | 8:00AM - 11:15AM
Immune Checkpoints: Basic Mechanisms and Novel Targets
Room: Sea to Sky B/C

Speaker 5 of 8
* Xiaoyan Michelle Zhang, Kyn Therapeutics, USA
Kynureninase and AHR Inhibition, Novel and Differentiated Approaches Targeting IDO1/TDO2/Kynurenine Pathway and Beyond

Wednesday, March 13 | 8:00AM - 11:15AM
Immune Checkpoints: Basic Mechanisms and Novel Targets
Room: Sea to Sky B/C

Speaker 6 of 8
Martina Seiffert, German Cancer Research Center, Germany
Short Talk: IL-10/STAT3 Signaling Overcomes Tumor-Induced Exhaustion of CD8+ T-Cells

Wednesday, March 13 | 8:00AM - 11:15AM
Immune Checkpoints: Basic Mechanisms and Novel Targets
Room: Sea to Sky B/C

Speaker 7 of 8
Dana Emerson, Oregon Health and Science University, USA
Short Talk: ITK Inhibition Augments the Therapeutic Efficacy of anti-OX40/anti-CTLA-4 Immunotherapy via Enhanced Eomes Expression and Effector T-Cell Responses

Wednesday, March 13 | 8:00AM - 11:15AM
Immune Checkpoints: Basic Mechanisms and Novel Targets
Room: Sea to Sky B/C

Speaker 8 of 8
Tao Dong, University of Oxford, UK
Short Talk: A Comprehensive Analysis of Key Immune Checkpoint Receptors on T Cells Indicates Mono-or Combinatorial Blockade Immunotherapy in Multiple Types of Cancer

Wednesday, March 13 | 11:15AM - 5:00PM
On Own for Lunch


Wednesday, March 13 | 11:15AM - 1:00PM
Poster Setup
Room: Sea to Sky A


Wednesday, March 13 | 1:00PM - 10:00PM
Poster Viewing
Room: Sea to Sky A


Wednesday, March 13 | 4:30PM - 5:00PM
Coffee Available
Room: Grand Foyer


Wednesday, March 13 | 5:00PM - 7:00PM
Combinatorial Immunotherapy Strategies
Room: Sea to Sky B/C

Speaker 1 of 5
* Sandra Demaria, Weill Cornell Medical College, USA
Using Precision Radiotherapy to Ignite Anti-Tumor Immunity with Immunotherapy

Wednesday, March 13 | 5:00PM - 7:00PM
Combinatorial Immunotherapy Strategies
Room: Sea to Sky B/C

Speaker 2 of 5
Juan C. Jaen, Arcus Biosciences, Inc., USA
Targeting Immune Activation via Inhibition of the Adenosine Pathway

Wednesday, March 13 | 5:00PM - 7:00PM
Combinatorial Immunotherapy Strategies
Room: Sea to Sky B/C

Speaker 3 of 5
* Antoni Ribas, University of California, Los Angeles, USA
Novel Combination Therapy Strategies

Wednesday, March 13 | 5:00PM - 7:00PM
Combinatorial Immunotherapy Strategies
Room: Sea to Sky B/C

Speaker 4 of 5
Peter Goff, University of Washington, USA
Short Talk: Newcastle Disease Virus Works Synergistically with Radiotherapy to Enhance Checkpoint Blockade and Improve Long-Term Survival in a Murine Melanoma Model

Wednesday, March 13 | 5:00PM - 7:00PM
Combinatorial Immunotherapy Strategies
Room: Sea to Sky B/C

Speaker 5 of 5
Sarah L. Buchan, University of Southampton, UK
Short Talk: PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs that Synergize for CD8+ T-Cell Driven Anti-Tumor Immunity

Wednesday, March 13 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Sea to Sky A
No registration fees are used to fund alcohol served at this function.

Wednesday, March 13 | 7:30PM - 10:00PM
Poster Session 3
Room: Sea to Sky A


Thursday, March 14 | 7:00AM - 8:00AM
Breakfast
Room: Grand Foyer


Thursday, March 14 | 8:00AM - 11:15AM
Progress Report on Immune Monitoring and Clinical Trials
Room: Sea to Sky B/C

Speaker 1 of 8
Robert H. Vonderheide, University of Pennsylvania, USA
Immunogenic Properties of Mutant KRAS

Thursday, March 14 | 8:00AM - 11:15AM
Progress Report on Immune Monitoring and Clinical Trials
Room: Sea to Sky B/C

Speaker 2 of 8
Ton N. Schumacher, Netherlands Cancer Institute, Netherlands
Regulation of Immune Recognition by the CD47 and PD-L1 Immune Checkpoints

Thursday, March 14 | 8:00AM - 11:15AM
Progress Report on Immune Monitoring and Clinical Trials
Room: Sea to Sky B/C


Coffee Break

Thursday, March 14 | 8:00AM - 11:15AM
Progress Report on Immune Monitoring and Clinical Trials
Room: Sea to Sky B/C

Speaker 4 of 8
* Sumit Kumar Subudhi, MD Anderson Cancer Center, USA
Immune Checkpoint Therapies in Prostate Cancer

Thursday, March 14 | 8:00AM - 11:15AM
Progress Report on Immune Monitoring and Clinical Trials
Room: Sea to Sky B/C

Speaker 5 of 8
* Cornelia Liu Trimble, Johns Hopkins University School of Medicine, USA
Therapeutic Vaccination for Intraepithelial Disease: Lessons Learned from HPV

Thursday, March 14 | 8:00AM - 11:15AM
Progress Report on Immune Monitoring and Clinical Trials
Room: Sea to Sky B/C

Speaker 6 of 8
Hideho Okada, University of California, San Francisco, USA
Short Talk: Targeting H3.3 K27M Mutation as a Shared Neoantigen in HLA-A*0201+ Patients with Diffuse Midline Gliomas – Development of a Novel Mass Cytometry-Based Monitoring of Vaccine-Reactive, Epitope-Specific CD8+ T Cell Responses

Thursday, March 14 | 8:00AM - 11:15AM
Progress Report on Immune Monitoring and Clinical Trials
Room: Sea to Sky B/C

Speaker 7 of 8
Akil A. Merchant, Cedars-Sinai Medical Center, USA
Short Talk: Highly Multiplexed Imaging Mass Cytometry Reveals Immune Cell Composition and Spatial Heterogeneity in Diffuse Large B Cell Lymphoma Associated with Treatment Outcome

Thursday, March 14 | 8:00AM - 11:15AM
Progress Report on Immune Monitoring and Clinical Trials
Room: Sea to Sky B/C

Speaker 8 of 8
Colleen Annesley, Seattle Children's Hospital, USA
Short Talk: Novel CD19t T-Antigen-Presenting Cells Expand CD19 CAR T Cells in vivo

Thursday, March 14 | 11:15AM - 5:00PM
On Own for Lunch


Thursday, March 14 | 2:30PM - 4:30PM
Workshop 3: Engineering Novel Therapeutic Agents
Room: Sea to Sky B/C

Speaker 1 of 6
Michael Schebesta, Obsidian Therapeutics, USA
Enhancing Adoptive Cell Therapies Through Regulation of CD40L

Thursday, March 14 | 2:30PM - 4:30PM
Workshop 3: Engineering Novel Therapeutic Agents
Room: Sea to Sky B/C

Speaker 2 of 6
* Nadia Coltella, Universita' Vita-Salute San Raffaele, Italy
Development of Chimeric Forms of IFN-a for Inducible in vivo Cancer Gene Therapy

Thursday, March 14 | 2:30PM - 4:30PM
Workshop 3: Engineering Novel Therapeutic Agents
Room: Sea to Sky B/C

Speaker 3 of 6
Sriram Sathyanarayanan, Codiak BioSciences, USA
Developing an Engineered Exosome Therapeutic Platform for Immuno-Oncology

Thursday, March 14 | 2:30PM - 4:30PM
Workshop 3: Engineering Novel Therapeutic Agents
Room: Sea to Sky B/C

Speaker 4 of 6
Chris Saxby, University of Washington, USA
Engineered Cytokine Receptors Support CAR T Cell Mediated Tumor Removal

Thursday, March 14 | 2:30PM - 4:30PM
Workshop 3: Engineering Novel Therapeutic Agents
Room: Sea to Sky B/C

Speaker 5 of 6
* Sara Schad, Memorial Sloan Kettering Cancer Center, USA
Phosphatidylserine Targeting Antibody Enhances Anti-Tumor Activity of CAR T Cell Therapy in a Mouse Melanoma Model

Thursday, March 14 | 2:30PM - 4:30PM
Workshop 3: Engineering Novel Therapeutic Agents
Room: Sea to Sky B/C

Speaker 6 of 6
Scott T. Walsh, NCI, National Institutes of Health, USA
Development of a Novel Interleukin-7 Hydrogel Delivery System for T cell Applications

Thursday, March 14 | 4:30PM - 5:00PM
Coffee Available
Room: Grand Foyer


Thursday, March 14 | 5:00PM - 6:45PM
The Future of Cancer Immunotherapy
Room: Sea to Sky B/C

Speaker 1 of 4
* Jennifer Ann Wargo, University of Texas MD Anderson Cancer Center, USA
Microbiome Targeting and Future Strategies to Improve Cancer Immunotherapy

Thursday, March 14 | 5:00PM - 6:45PM
The Future of Cancer Immunotherapy
Room: Sea to Sky B/C

Speaker 2 of 4
* Michael C. Jensen, Seattle Children's Research Institute, USA
Regulating the Next Generation of Genetically Enhanced CAR T Cells

Thursday, March 14 | 5:00PM - 6:45PM
The Future of Cancer Immunotherapy
Room: Sea to Sky B/C

Speaker 3 of 4
Flavius Martin, Amgen, Inc., USA
Learnings from Bispecific T-Cell Engagers, from Bedside Back to the Bench

Thursday, March 14 | 5:00PM - 6:45PM
The Future of Cancer Immunotherapy
Room: Sea to Sky B/C

Speaker 4 of 4
Darren Austin Plumb, PsiOxus Therapeutics, UK
Short Talk: Development of an Oncolytic T-SIGn Virus, NG-641, Targeting Cancer-Associated Fibroblasts for the Treatment of Stroma-Rich Carcinomas

Thursday, March 14 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Sea to Sky B/C


Thursday, March 14 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Sea to Sky A
No registration fees are used to fund alcohol served at this function.

Thursday, March 14 | 8:00PM - 11:00PM
Entertainment
Room: Sea to Sky A
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, March 14 | 8:00PM - 11:00PM
Cash Bar
Room: Sea to Sky A


Friday, March 15 | 10:24AM - 10:24AM
Departure


*Session Chair
†Invited, not yet responded.